Repare Therapeutics Inc. (RPTX)
NASDAQ: RPTX · Real-Time Price · USD
2.200
+0.060 (2.80%)
At close: Dec 15, 2025, 4:00 PM EST
2.220
+0.020 (0.91%)
After-hours: Dec 15, 2025, 5:27 PM EST
Repare Therapeutics Employees
Repare Therapeutics had 129 employees as of December 31, 2024. The number of employees decreased by 50 or -27.93% compared to the previous year.
Employees
129
Change (1Y)
-50
Growth (1Y)
-27.93%
Revenue / Employee
$92,016
Profits / Employee
-$559,690
Market Cap
94.57M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 129 | -50 | -27.93% |
| Dec 31, 2023 | 179 | -1 | -0.56% |
| Dec 31, 2022 | 180 | 28 | 18.42% |
| Dec 31, 2021 | 152 | 50 | 49.02% |
| Dec 31, 2020 | 102 | 38 | 59.38% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RPTX News
- 25 days ago - Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc. - Business Wire
- 27 days ago - Halper Sadeh LLC Encourages RPTX and SEE Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewsWire
- 4 weeks ago - Repare Therapeutics Agrees To Acquisition As Board Cites Best Path For Stakeholder Value - Benzinga
- 4 weeks ago - Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc. - Business Wire
- 2 months ago - Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Business Wire
- 4 months ago - Repare (RPTX) Q2 Loss Narrows 52% - The Motley Fool
- 4 months ago - Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results - Business Wire
- 5 months ago - Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib - Business Wire